MedTrace Logo

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer.

The names of the therapies involved in this study are:

* PD-L1 t-haNK cell therapy (a NK cell therapy infusion)
* NAI (a type of recombinant human superagonist)
* Cetuximab (a type of antibody)

Conditions

Interventions

BIOLOGICAL

PD-L1 t-haNK

Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.

DRUG

Cetuximab

Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.

BIOLOGICAL

NAI

Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.

Sponsors & Collaborators

  • ImmunityBio, Inc.

    collaborator INDUSTRY

  • Glenn J. Hanna

    lead OTHER

Principal Investigators

  • Glenn J Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-16
Primary Completion
2026-07-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06239220 on ClinicalTrials.gov